✦ LIBER ✦

Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting

✍ Scribed by J. Pater; L. Slamet; B. Zee; D. Osoba; D. Warr; J. Rusthoven

Publisher: Springer-Verlag
Year: 1994
Tongue: English
Weight: 538 KB
Volume: 2
Category: Article
ISSN: 0941-4355
DOI: 10.1007/bf00417474

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Levonantradol for the treatment of chemo

Levonantradol for the treatment of chemotherapy-induced nausea and vomiting

✍ Gerhartz, H. H. ;Binsack, T. ;Hiller, E. 📂 Article 📅 1983 🏛 Springer-Verlag 🌐 English ⚖ 237 KB

An effective five-drug antiemetic combin

An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting

✍ John F. Kessler; David S. Alberts; Patricia M. Plezia; Vicki Wilson; Judy Chase; 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 475 KB

Test-retest reliability and concurrent v

Test-retest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy-related nausea and vomiting

✍ C. L. M. Carnrike; Phillip J. Brantley; Barbara Bruce; Shaista Faruqui; Frank M. 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 445 KB

Continuous infusion of high-dose metoclo

Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy

✍ R. A. Joss; R. L. Galeazzi; K. W. Brunner 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 580 KB

High versus low dose granisetron, a sele

High versus low dose granisetron, a selective 5HT3antagonist, for the prevention of chemotherapy-induced nausea and vomiting

✍ H. C. Falkson; C. I. Falkson; G. Falkson 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 173 KB

Fifty six patients, with histologically confirmed cancer, who received highly emetogenic chemotherapy, were entered on a randomized double blind, low versus high dose, study of granisetron, a 5HT3 receptor antagonist. A single dose of intravenous granisetron protected the majority of patients from n

Establishing the dose of the oral NK1 an

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting

✍ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract ## BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to